Yarrow goes public while Otsuka receives FDA approval for new ADHD medication

Yarrow Bioscience completed a merger that took the company public and will now trade under its own ticker. The firm is developing an anti-TSHR antibody aimed at treating Graves’ disease and the associated thyroid eye disease.

The public listing gives Yarrow access to capital as it advances its candidate through clinical testing, targeting the autoimmune condition that causes overactive thyroid and eye complications.

In separate news, the U.S. Food and Drug Administration approved Otsuka Pharmaceutical’s new ADHD medication, adding another treatment option for patients with attention-deficit hyperactivity disorder.